Fig. 3: F16BP(pTRP2+PolyIC) MPs promote a pro-inflammatory response against melanoma, in vivo.
From: Rescue of dendritic cells from glycolysis inhibition improves cancer immunotherapy in mice
a Schematic representation of subcutaneous injection of Vacc MPs, in vivo, b Kaplan–Meir curve demonstrating significantly higher survival of mice treated with Vacc MPs, c, d Mice treated with Vacc MPs had a significantly higher percentage of the total as well as activated DCs in the draining lymph (n = 5; One-way ANOVA Tukey’s test), e, f Mice treated with Vacc MPs had significantly higher number of Tc and activated and proliferating Tc as compared to other treatment groups (n = 4 or 5; One-way ANOVA Tukey’s test), g No significant differences in the number of Tregs was observed across treatment groups (n = 5; One-way ANOVA Tukey’s test), h–k Mice treated with Vacc MPs had significantly higher number of Tc, Tc1, activated and proliferating Tc1 and Tc17 cells (n = 4; One-way ANOVA Tukey’s test), l Significantly higher Tc1/Treg ratio was observed in mice treated with Vacc MPs as compared to the control groups (n = 4; One-way ANOVA Tukey’s test). Data represented as mean ± std error.
